Amit Vora, MD
Endocrinology, Diabetes & Metabolism · Knoxville, TNNPI 1982745808
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $506,823 of the $579,329 with a category attached, or 87.5%. 50 manufacturers reported payments, led by Novo Nordisk at 39.7% of the total. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,309 payments — averaging $442.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$230K
- Lilly USA, LLC$176K
- Boehringer Ingelheim$42K
- Abbott$37K
- Dexcom, Inc.$36K
- Bayer$18K
- plus $40K from 44 others
Across 2 payments — averaging $37.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$38
- GSK$38
What the payments were for
- Consulting fees$23,3414%
- Speaking & faculty fees$506,82387%
- Travel & lodging$25,8354%
- Food & beverage$22,9574%
- Education$3730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$150,913
- RYBELSUS$91,563
- Ozempic$87,915
- JARDIANCE$58,532
- FREESTYLE LIBRE 3$35,935
- Tresiba$30,446
- DEXCOM G7 GSS (161)$20,326
- Kerendia$16,665
- AFREZZA$11,612
- DEXCOM G6 TRANSMITTER$6,357
- CRENESSITY$4,937
- DEXCOM G6 CGM SYSTEM$4,606
- Omnipod$4,500
- t:slim X2 insulin pump$3,750
- GVOKE HYPOPEN$3,420
- DEXCOM CGM$3,320
- t-slim insulin pump$2,650
- DEXCOM STELO GLUCOSE BIOSENSOR$2,404
- Xultophy 100/3.6$2,275
- FreeStyle Lite system$250
How this compares
$579,329 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $67,044 |
| MounjaroTirzepatide | 43 | $48,010 |
| JardianceEmpagliflozin | 56 | $45,246 |
| TradjentaLinagliptin | 14 | $11,645 |
| FarxigaDapagliflozin Propanediol | 14 | $8,928 |
| SynthroidLevothyroxine Sodium | 97 | $6,249 |
| Levothyroxine Sodium | 519 | $4,698 |
| Hydrocortisone | 46 | $2,963 |
| Bromocriptine Mesylate | 20 | $2,928 |
| Methimazole | 61 | $712 |
| Metformin Hcl ErMetformin Hcl | 44 | $708 |
| Prednisone | 28 | $520 |
| Ibandronate Sodium | 24 | $483 |
| Repaglinide | 15 | $471 |
| Pioglitazone Hcl | 32 | $363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $230,262 | $67,04452 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42,428 | $56,89170 claims |
| Lilly USA, LLCMounjaro | $175,972 | $48,01043 claims |
| AstraZenecaFarxiga | $276 | $8,92814 claims |
| AbbVieSynthroid | $71 | $6,24997 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $58 | $4,698519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Knoxville
- David IrizarryKnoxville$96K
- Casey PageKnoxville$82K
- Mubashir MahmoodKnoxville$26K
- Thomas DotyKnoxville$21K
- Daniel McCammonKnoxville$9K
- Peter CampbellKnoxville$5K
- Gregory MoffittKnoxville$5K
- Robert GeierKnoxville$4K
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.